Skip to main content
. 2017 Apr 1;7(4):831–844.

Figure 3.

Figure 3

MEK inhibits proliferation and turns off ERK signaling in tumor cells carrying NRASQ61K. A. Proliferation of H1299 and H2087 cells were assessed with kinase inhibitors. Data are from three independent experiments and are mean ± SD. n = 3, **P < 0.01, compared to control. B. The proliferation inhibitory effects of trametinib on H1299 and H2087 cells were abolished by NRASQ61K siRNA. Data are from three independent experiments and are mean ± SD. n = 3, **P < 0.01 versus control. C. Biochemical analysis of phospho-ERK and phospho-AKT (Ser473 and Thr308) in H1299 and H2087. GAPDH was used as loading control. D. Co-immunoprecipitation (IP) of B-Raf and C-Raf with RAS from NRASQ61K cell lines after treatment with trametinib. Data were from three independent experiments. WCL, whole cell lysate.